| 1 |
Approval of clinical trial plan for mitochondrial transplantation therapy for the treatment of Parkinson's disease |
| Other-Bio. |
Parkinson's disease |
Mitochondiral defects |
Preclinical |
PAEAN biothechnology Inc. |
RS-2026-25503094 |
|
| 2 |
Nonclinical Study to Support IND Submission for ZC311, a Novel Lysosome-Activating Small Peptide Therapeutic Candidate for Amyotrophic Lateral Sclerosis (ALS) |
| rProtein |
ALS |
lysosome |
Preclinical |
Zincure Corp. |
RS-2026-25502282 |
|
| 3 |
Preclinical development of an HDAC6 inhibitor targeting Axonal Transport dysfunction in Charcot-Marie-Tooth Disease |
| Small molecules |
Charco-Marie-Tooth disease |
HDAC6 |
Preclinical |
Chong Kun Dang |
RS-2025-25454943 |
|
| 4 |
Pre-clinical study of ASO drug for treating Parkinson's disease |
| Gene & Nucleic acids |
Parkinson's disease |
Undisclosed |
Preclinical |
HLB Neurotobe |
RS-2025-02223597 |
|
| 5 |
Non-clinical development of new selective allosteric TrkA inhibitor for pain treatment |
| Small molecules |
Osteoarthritis pain |
TrkA, TRPV1 |
Preclinical |
Mother’s Pharmaceutical Co., Ltd. |
RS-2025-02213103 |
|
| 6 |
Nonclinical efficacy and safety evaluation of an LRRK2 inhibitor candidate for the development of a disease-modifying Parkinson’ s disease therapy and subsequent IND approval |
| Small molecules |
Parkinson's disease |
LRRK2 |
Preclinical |
Novorex Inc. |
RS-2025-02213047 |
|
| 7 |
Non-clinical study for developing a gene therapy of spinal cord injury using cell fate conversion |
| Gene & Nucleic acids |
Spinal Cord Injury, SCI |
Non-neuronal cells (Astrocytic scar, Glial scar, fibroblasts and etc.） |
Preclinical |
Stand Up Therapeutics |
RS-2025-02173013 |
|
| 8 |
Non-clinical studies of LMT801 for the treatment of Charcot- Marie-Tooth Disease Type 1A (CMT1A) |
| Small molecules |
Charcot-Marie-Tooth disease type 1A |
NQO1 |
Preclinical |
Lmito Therapeutics |
RS-2025-02073078 |
|
| 9 |
Non.clinical study completion and manufacturing system development of CX301 for the development of orphan drug on malignant ischemic stroke |
| Others-Synth. |
Cerebral infarction |
ROS.related inflammation |
Preclinical |
Cenyx Biotech Inc. |
RS-2023-00284156 |
|
| 10 |
Non.clinical development of ALS disease treatment using a small molecule compound that inhibits aggregation of SOD1 protein |
| Small molecules |
Amyotrophic Lateral Sclerosis |
SOD1 |
Preclinical |
PRG S&Tech Inc. |
RS-2023-00258714 |
|
| 11 |
Pre-clinical development of AAV-CRISPR-based PMP22 normalization gene therapy for Charcot-Marie-Tooth 1A |
| Gene & Nucleic acids |
Charcot-Marie-Tooth disease type 1A |
PMP22 |
Preclinical |
ToolGen, Inc |
HN22C0431 |
|
| 12 |
Development of eIF4E ASO treating childhood intractable epilepsy as a first-in-class drug and establishment of R&D environment for RNA therapeutics |
| Gene & Nucleic acids |
FCDII Refractory epilepsy |
eIF4E |
Preclinical |
SoVarGen Co., Ltd. |
HN21C0617 |
|